Ovarian Epithelial Tumor
Associated Genetic Biomarkers
NCI Definition: A benign, borderline, or malignant tumor that originates from the surface epithelium of the ovary. It is composed of epithelial cells and stroma. Representative examples of benign tumors include serous cystadenoma, mucinous cystadenoma, and benign Brenner tumor. Representative examples of borderline tumors include serous surface papillary tumor, mucinous adenofibroma, and borderline Brenner tumor. Representative examples of malignant tumors include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, and malignant Brenner tumor. 
Ovarian epithelial tumors most frequently harbor alterations in TP53, KRAS, PIK3CA, ARID1A, and CCNE1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and TP53 Frameshift are the most common alterations in ovarian epithelial tumor .
There are 4 clinical trials for ovarian epithelial tumor, of which 4 are open and 0 are completed or closed. Of the trials that contain ovarian epithelial tumor as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open).
EGFR and ERBB2 are the most frequent gene inclusion criteria for ovarian epithelial tumor clinical trials .
Rrx-001, bevacizumab, and carboplatin are the most common interventions in ovarian epithelial tumor clinical trials.
Significant Genes in Ovarian Epithelial Tumor
EGFR is altered in 0.88% of ovarian epithelial tumor patients .
EGFR is an inclusion eligibility criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) .
ERBB2 is altered in 3.07% of ovarian epithelial tumor patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.